We are live on
!
Find out more
SCM
Sarissa Capital Management Portfolio holdings
AUM
$158M
1-Year Est. Return
103.7%
This Fund
S&P 500
This Quarter
Est. Return
-17.9%
1 Year Est. Return
+103.7%
3 Year Est. Return
+58.62%
5 Year Est. Return
+92.85%
10 Year Est. Return
+667.68%
AUM
$267M
AUM Growth
–
Cap. Flow
+$247M
Cap. Flow
% of AUM
92.6%
Top 10 Holdings %
Top 10 Hldgs %
95.5%
Holding
12
New
12
Increased
–
Reduced
–
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ARIA
Ariad Pharmaceuticals Inc
ARIA
|
+$64.8M |
| 2 |
Quest Diagnostics
DGX
|
+$41.5M |
| 3 |
VVUS
Vivus Inc
VVUS
|
+$24.9M |
| 4 |
IDIX
IDENIX PHARMACEUTICALS INC
IDIX
|
+$23.4M |
| 5 |
Merck
MRK
|
+$19.2M |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 85.96% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ARIA
1
DELISTED
Ariad Pharmaceuticals Inc
ARIA
| $81.8M | 30.65% |
+12,000,000
| New | +$64.8M |
|
|
2
Quest Diagnostics
DGX
$25.7B
| $37.5M | 14.04% |
+700,000
| New | +$41.5M |
|
|
IDIX
3
DELISTED
IDENIX PHARMACEUTICALS INC
IDIX
| $30.2M | 11.31% |
+5,050,100
| New | +$23.4M |
|
|
VVUS
4
DELISTED
Vivus Inc
VVUS
| $23.4M | 8.75% |
+257,394
| New | +$24.9M |
|
|
5
Merck
MRK
$322B
| $20M | 7.5% |
+419,200
| New | +$19.2M |
|
|
MNK
6
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
| $14.6M | 5.48% |
+280,000
| New | +$13.3M |
|
7
Bristol-Myers Squibb
BMY
$133B
| $13.3M | 4.98% |
+250,000
| New | +$12.7M |
|
8
AbbVie
ABBV
$443B
| $13.2M | 4.94% |
+250,000
| New | +$12.3M |
|
9
Pfizer
PFE
$143B
| $12.6M | 4.7% |
+432,140
| New | +$12.6M |
|
|
RPRX
10
DELISTED
Repros Therapeutics Inc.
RPRX
| $8.41M | 3.15% |
+459,508
| New | +$8.68M |
|
|
BRLI
11
DELISTED
BIO-REFERENCE LABS INC-NEW-
BRLI
| $7.29M | 2.73% |
+285,300
| New | +$8.79M |
|
|
AVEO
12
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
| $4.73M | 1.77% |
+257,076
| New | +$5.15M |
|
Similar funds
4A
DAM
PCP
CF
HEM
SF
AC
EP
Sarissa Capital Management's Q4 2013 Portfolio in Review
Q4 2013 is the first quarter with a 13F filing on record for Sarissa Capital Management, which disclosed 12 positions worth $267M. Its ten largest holdings account for 95% of the portfolio.
Its largest position is Ariad Pharmaceuticals Inc: 12,000,000 shares worth $81.8M.
By sector, the portfolio is most concentrated in Healthcare at 86% of assets.
- Sarissa Capital Management's largest Q4 2013 buy was Ariad Pharmaceuticals Inc: 12,000,000 shares worth $81.8M.
- Sarissa Capital Management's ten largest holdings make up 95% of its $267M portfolio in Q4 2013.
- Sarissa Capital Management disclosed 12 positions in Q4 2013, its first 13F filing on record.
Based on Sarissa Capital Management's 13F filing for Q4 2013, filed 14 Feb 2014.